The role of platelet inhibition in the drug-eluting stent era.
The use of antiplatelet agents in the management of patients undergoing percutaneous coronary interventions involves the administration of aspirin, thienopyridines, and in high-risk patients, GPIIb-IIIa antagonists. Drug-eluting stents now account for greater than 50% of stenting procedures. This review focuses on the limited available data describing the use of antiplatelet agents in patients undergoing drug-eluting stent implantation.
Tamberella
Michael R
MR
Department of Medicine and the Center for Platelet Function Studies, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, MA 01655, USA.
Furman
Mark I
MI
D001241:Aspirin / Q000627:therapeutic use*; D023921:Coronary Stenosis / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011725:Pyridines / Q000627:therapeutic use*; D015607:Stents
D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011725:Pyridines; C446540:thienopyridine; D001241:Aspirin